Advanced search
Publication Cover
Acta Oncologica Volume 56, 2017 - Issue 3
Journal homepage
3,723
Views
66
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLES: PANCREATIC CANCER

Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy

Eric A. MellonDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA; ;Department of Radiation Oncology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida, USA;
,
William H. JinDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA;
,
Jessica M. FrakesDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA;
,
Barbara A. CentenoDepartment of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA;
,
Tobin J. StromDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA;
,
Gregory M. SpringettGastrointestinal Tumor Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA;
,
Mokenge P. MalafaGastrointestinal Tumor Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA;
,
Ravi ShridharDepartment of Radiation Oncology, Florida Hospital Cancer Institute, Orlando, Florida, USA
,
Pamela J. HodulGastrointestinal Tumor Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA;
&
Sarah E. HoffeDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA; Correspondence[email protected]
 show all
Pages 391-397 | Received 22 Jun 2016, Accepted 24 Oct 2016, Published online: 25 Nov 2016

Citations (66)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Patrick M McCarthy, Matthew J Rendo, Matthew D Uy, Alexandra M Adams, Anne E O’Shea, Daniel William Nelson, Joshua L Fenderson, Katherine M Cebe, Robert W Krell, Guy T Clifton, George E Peoples & Timothy J Vreeland. (2021) Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Ductal Adenocarcinoma. OncoTargets and Therapy 14, pages 3537-3544.
Read now
Erkut Borazanci, Steven Sckolnik & Albert Amini. (2019) Neo-adjuvant therapy for pancreatic cancer: hope for the future. Expert Review of Gastroenterology & Hepatology 13:6, pages 579-589.
Read now

Articles from other publishers (64)

Rita C. Akumuo, Anthony M. Villano, Sai P. Reddy, Karthik Devarajan, Dany Barrak & Sanjay S. Reddy. (2024) Type of neoadjuvant treatment strategy is associated with differential pathologic responses in pancreatic ductal adenocarcinoma. The American Journal of Surgery 232, pages 9-14.
Crossref
Krishan R. Jethwa, Ed Kim, Jordan Berlin, Christopher J. Anker, Leila Tchelebi, Gerard Abood, Christopher L. Hallemeier, Salma Jabbour, Timothy Kennedy, Rachit Kumar, Percy Lee, Navesh Sharma, William Small, Vonetta Williams & Suzanne Russo. (2024) Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma. American Journal of Clinical Oncology 47:4, pages 185-199.
Crossref
Carolina de la Pinta. (2024) Stereotactic body radiotherapy in pancreatic adenocarcinoma. Hepatobiliary & Pancreatic Diseases International 23:1, pages 14-19.
Crossref
Jeongin Yoo, Jeong Min Lee, Ijin Joo, Dong Ho Lee, Jeong Hee Yoon, Mi Hye Yu, Jin-Young Jang & Sang Hyub Lee. (2023) Post-neoadjuvant treatment pancreatic cancer resectability and outcome prediction using CT, 18F-FDG PET/MRI and CA 19–9. Cancer Imaging 23:1.
Crossref
Heng‐Chung Kung & Jun Yu. (2023) Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study. MedComm 4:2.
Crossref
Ahmed SAIDANI, Anis BELHADJ, Khefacha Fahd, Hichem RAKKEH, Mohamed Raouf BEN OTHMENE & Faouzi CHEBBI. (2023) Case Report: complete pathological response after chemotherapy for borderline pancreatic cancer. F1000Research 12, pages 1268.
Crossref
Yoshihiro Ono, Yosuke Inoue, Hiromichi Ito, Takashi Sasaki, Tsuyoshi Takeda, Masato Ozaka, Naoki Sasahira, Makiko Hiratsuka, Kiyoshi Matsueda, Atsushi Oba, Takafumi Sato, Akio Saiura & Yu Takahashi. (2023) Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with elevated pre-chemotherapy CA19-9 levels. HPB 25:1, pages 100-108.
Crossref
J.M. Bryant, Russell F. Palm, Casey Liveringhouse, Emanuel Boyer, Pam Hodul, Mokenge Malafa, Jason Denbo, Dae Kim, Estrella Carballido, Jason B. Fleming, Sarah Hoffe & Jessica Frakes. (2022) Surgical and Pathologic Outcomes of Pancreatic Adenocarcinoma (PA) After Preoperative Ablative Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy (A-SMART). Advances in Radiation Oncology 7:6, pages 101045.
Crossref
F. Huguet, C. Cerbai, M.H. Ta, T. Sarrade, C. Evin, S. Aziez, E. Rivin del Campo, B. Durand & M. Loi. (2022) Neoadjuvant treatment of pancreatic adenocarcinoma: Chemoradiation or stereotactic body radiation therapy?. Cancer/Radiothérapie 26:6-7, pages 858-864.
Crossref
Amro M. AbdelrahmanAjit H. GoenkaRoberto Alva-RuizJennifer A. YonkusJennifer L. LeitingRondell P. GrahamKenneth W. Merrell, Cornelius A. ThielsChristopher L. Hallemeier, Susanne G. WarnerMichael G. Haddock, Travis E. GrotzNguyen H. TranRory L. SmootWen Wee MaSean P. ClearyRobert R. McWilliamsDavid M. NagorneyThorvardur R. HalfdanarsonMichael L. KendrickMark J. Truty. (2022) FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. Journal of the National Comprehensive Cancer Network 20:9, pages 1023-1032.e3.
Crossref
Hironobu Suto, Keiichi Okano, Minoru Oshima, Yasuhisa Ando, Hiroyuki Matsukawa, Shigeo Takahashi, Toru Shibata, Hideki Kamada, Tsutomu Masaki & Yasuyuki Suzuki. (2022) Prediction of local tumor control and recurrence‐free survival in patients with pancreatic cancer undergoing curative resection after neoadjuvant chemoradiotherapy. Journal of Surgical Oncology 126:2, pages 292-301.
Crossref
Mansour Bahardoust, Mohammad Ali Abyazi, Sayed Ali Emami, Parmida Ghadimi, Mehrdad Khodabandeh, Farhad Mahmoudi, Ramin Hosseinzadeh, Mohammad Heiat & Shahram Agah. (2021) Predictors of survival rate in patients with pancreatic cancer: A multi‐center analytical study in Iran. Cancer Reports 5:8.
Crossref
Garrett Simpson, William Jin, Benjamin Spieler, Lorraine Portelance, Eric Mellon, Deukwoo Kwon, John C. Ford & Nesrin Dogan. (2022) Predictive Value of Delta-Radiomics Texture Features in 0.35 Tesla Magnetic Resonance Setup Images Acquired During Stereotactic Ablative Radiotherapy of Pancreatic Cancer. Frontiers in Oncology 12.
Crossref
Hironobu Suto, Keiichi Okano, Minoru Oshima, Yasuhisa Ando, Hiroyuki Matsukawa, Shigeo Takahashi, Toru Shibata, Hideki Kamada, Hideki Kobara, Akihito Tsuji, Tsutomu Masaki & Yasuyuki Suzuki. (2022) Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderline Resectable Pancreatic Cancer. Pancreas 51:3, pages 269-277.
Crossref
Farshad Moradi & Andrei Iagaru. 2022. Nuclear Medicine and Molecular Imaging. Nuclear Medicine and Molecular Imaging 252 267 .
Georgios Kaissis & Rickmer Braren. 2022. Artificial Intelligence/Machine Learning in Nuclear Medicine and Hybrid Imaging. Artificial Intelligence/Machine Learning in Nuclear Medicine and Hybrid Imaging 159 170 .
Woohyung Lee, Minyoung Oh, Jae Seung Kim, Yejong Park, Jae Woo Kwon, Eunsung Jun, Ki Byung Song, Jae Hoon Lee, Dae Wook Hwang, Changhoon Yoo, Kyu-Pyo Kim, Jae Ho Jeong, Heung-Moon Chang, Baek-Yeol Ryoo, Seo Young Park & Song Cheol Kim. (2022) Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival. British Journal of Surgery 109:1, pages 61-70.
Crossref
William A. Hall, Laura A. Dawson, Theodore S. Hong, Manisha Palta, Joseph M. Herman, Douglas B. Evans, Susan Tsai, Cristina R. Ferrone, Jason B. Fleming, Daniel T. Chang, Christopher Crane, Albert C. Koong, Andrew Oar, Parag Parikh, Beth Erickson, Sarah Hoffe & Karyn A. Goodman. (2021) Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. Journal of Clinical Oncology 39:34, pages 3773-3777.
Crossref
Yasuhiro Murata, Shugo Mizuno, Masashi Kishiwada, Katsunori Uchida, Daisuke Noguchi, Kazuyuki Gyoten, Aoi Hayasaki, Takehiro Fujii, Yusuke Iizawa, Akihiro Tanemura, Naohisa Kuriyama, Hiroyuki Sakurai & Shuji Isaji. (2021) Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic ductal adenocarcinoma. Pancreatology 21:8, pages 1482-1490.
Crossref
Federica Vernuccio, Carlo Messina, Valeria Merz, Roberto Cannella & Massimo Midiri. (2021) Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine. Diagnostics 11:11, pages 2166.
Crossref
Liqiong Yang, Yun Bai, Qing Li, Jie Chen, Fangfang Liu, Xiechuan Weng & Fan Xu. (2021) Analysis of the Curative Effect of Neoadjuvant Therapy on Pancreatic Cancer. Frontiers in Oncology 11.
Crossref
Alex B. BlairLing-Di YinNing PuJun YuVincent P. GrootNoah S. RozichAmmar A. JavedLei ZhengJohn L. CameronRichard A. BurkhartMatthew J. WeissChristopher L. WolfgangJin He. (2021) Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer. Annals of Surgery 274:1, pages 162-169.
Crossref
Sara J. Zakem, Adam C. Mueller, Cheryl Meguid, Robert J. Torphy, Douglas E. Holt, Tracey Schefter, Wells A. Messersmith, Martin D. McCarter, Marco Del Chiaro, Richard D. Schulick & Karyn A. Goodman. (2021) Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer. HPB 23:7, pages 1072-1083.
Crossref
Savio George Barreto, Shailesh V. Shrikhande & Bhawna Sirohi. (2021) Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer. Indian Journal of Surgical Oncology.
Crossref
Laura Evangelista, Pietro Zucchetta, Lucia Moletta, Simone Serafini, Gianluca Cassarino, Nicola Pegoraro, Francesca Bergamo, Cosimo Sperti & Diego Cecchin. (2021) The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review. Annals of Nuclear Medicine 35:7, pages 767-776.
Crossref
Sae-Jin Park, Jung Hoon Kim, Ijin Joo, Kyoung Bun Lee & Joon Koo Han. (2020) Important CT and histopathological findings for recurrence and overall survival in patients with pancreatic ductal adenocarcinoma who underwent surgery after neoadjuvant FOLFIRINOX. European Radiology 31:6, pages 3616-3626.
Crossref
M. Tonneau, T. Lacornerie, X. Mirabel & D. Pasquier. (2021) Radiothérapie stéréotaxique dans le cancer du pancréas localement avancé : revue de la littérature. Cancer/Radiothérapie 25:3, pages 283-295.
Crossref
Asha Kandathil & Rathan M. Subramaniam. 2021. Imaging Diagnostics in Pancreatic Cancer. Imaging Diagnostics in Pancreatic Cancer 89 108 .
M. Unterrainer, C. Eze, H. Ilhan, S. Marschner, O. Roengvoraphoj, N. S. Schmidt-Hegemann, F. Walter, W. G. Kunz, P. Munck af Rosenschöld, R. Jeraj, N. L. Albert, A. L. Grosu, M. Niyazi, P. Bartenstein & C. Belka. (2020) Recent advances of PET imaging in clinical radiation oncology. Radiation Oncology 15:1.
Crossref
Martina Mori, Paolo Passoni, Elena Incerti, Valentino Bettinardi, Sara Broggi, Michele Reni, Phil Whybra, Emiliano Spezi, Elena G. Vanoli, Luigi Gianolli, Maria Picchio, Nadia G. Di Muzio & Claudio Fiorino. (2020) Training and validation of a robust PET radiomic-based index to predict distant-relapse-free-survival after radio-chemotherapy for locally advanced pancreatic cancer. Radiotherapy and Oncology 153, pages 258-264.
Crossref
Jordan M. Cloyd, Aslam Ejaz, Chengli Shen, Mary Dillhoff, Terence M. Williams, Anne Noonan, Timothy M. Pawlik & Allan Tsung. (2020) Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes. HPB 22:11, pages 1569-1576.
Crossref
Antolino Laura, Crovetto Anna, Matteo Cinquepalmi, Moschetta Giovanni, Mattei Maria Sole, Andrea Kazemi Nava, Petrucciani Niccolò, Nigri Giuseppe, Valabrega Stefano, Aurello Paolo, D’Angelo Francesco & Ramacciato Giovanni. (2020) Is Complete Pathologic Response in Pancreatic Cancer Overestimated? A Systematic Review of Prospective Studies. Journal of Gastrointestinal Surgery 24:10, pages 2336-2348.
Crossref
Farshad Moradi & Andrei Iagaru. (2020) The Role of Positron Emission Tomography in Pancreatic Cancer and Gallbladder Cancer. Seminars in Nuclear Medicine 50:5, pages 434-446.
Crossref
Naomi M. Sell, Grace C. Lee, Carlos Fernández-Del Castillo, Cristina R. Ferrone, Andrew L. Warshaw, Theodore S. Hong, Lawrence S. Blaszkowsky, Keith D. Lillemoe & Motaz Qadan. (2020) Evaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Pancreas 49:7, pages 897-903.
Crossref
Garrett Simpson, Benjamin Spieler, Nesrin Dogan, Lorraine Portelance, Eric A. Mellon, Deukwoo Kwon, John C. Ford & Fei Yang. (2020) Predictive value of 0.35 T magnetic resonance imaging radiomic features in stereotactic ablative body radiotherapy of pancreatic cancer: A pilot study. Medical Physics 47:8, pages 3682-3690.
Crossref
Michele Fiore, Silvia Taralli, Pasquale Trecca, Valentina Scolozzi, Luca Marinelli, Elizabeth K. A. Triumbari, Damiano Caputo, Silvia Angeletti, Massimo Ciccozzi, Alessandro Coppola, Carlo Greco, Edy Ippolito, Maria Lucia Calcagni, Roberto Coppola & Sara Ramella. (2020) A Bio-Imaging Signature as a Predictor of Clinical Outcomes in Locally Advanced Pancreatic Cancer. Cancers 12:8, pages 2016.
Crossref
Takahiro Yokose, Minoru Kitago, Yohji Matsusaka, Yohei Masugi, Masahiro Shinoda, Hiroshi Yagi, Yuta Abe, Go Oshima, Shutaro Hori, Yutaka Endo, Kenji Toyama, Yu Iwabuchi, Ryo Takemura, Ryota Ishii, Tadaki Nakahara, Shigeo Okuda, Masahiro Jinzaki & Yuko Kitagawa. (2020) Usefulness of 18 F‐fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant therapy for pancreatic ductal adenocarcinoma . Cancer Medicine 9:12, pages 4059-4068.
Crossref
Woohyung Lee, Yejong Park, Jae Woo Kwon, Eunsung Jun, Ki Byung Song, Jae Hoon Lee, Dae Wook Hwang, Changhoon Yoo, Kyu-pyo Kim, Jae Ho Jeong, Heung-Moon Chang, Baek-Yeol Ryoo, Seo Young Park & Song Cheol Kim. (2020) Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer. Journal of Clinical Medicine 9:5, pages 1477.
Crossref
Seifeldin Awad, Ahmad M. Alkashash, Magi Amin, Samantha J. Baker & J. Bart Rose. (2020) Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology 10.
Crossref
Andrew Oar, Mark Lee, Hien Le, George Hruby, Raymond Dalfsen, David Pryor, Dominique Lee, Julie Chu, Lois Holloway, Adam Briggs, Andrew Barbour, Sarat Chander, Sweet Ping Ng, Jas Samra, John Shakeshaft, David Goldstein, Nam Nguyen, Karyn A. Goodman, Daniel T. Chang & Andrew Kneebone. (2020) Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). Practical Radiation Oncology 10:3, pages e136-e146.
Crossref
Giampaolo Perri, Laura R. Prakash & Matthew H. G. Katz. (2020) Response to Preoperative Therapy in Localized Pancreatic Cancer. Frontiers in Oncology 10.
Crossref
David Wittmann, William A. Hall, Kathleen K. Christians, Chad A. Barnes, Neil R. Jariwalla, Mohammed Aldakkak, Callisia N. Clarke, Ben George, Paul S. Ritch, Matthew Riese, Abdul H. Khan, Naveen Kulkarni, John Evans, Beth A. Erickson, Douglas B. Evans & Susan Tsai. (2020) Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. Frontiers in Oncology 10.
Crossref
Atsushi Oba, Felix Ho, Quoc Riccardo Bao, Mohammed H. Al-Musawi, Richard D. Schulick & Marco Del Chiaro. (2020) Neoadjuvant Treatment in Pancreatic Cancer. Frontiers in Oncology 10.
Crossref
Michael Xiang, Gregory M. Heestand, Daniel T. Chang & Erqi L. Pollom. (2020) Neoadjuvant treatment strategies for resectable pancreas cancer: A propensity-matched analysis of the National Cancer Database. Radiotherapy and Oncology 143, pages 101-107.
Crossref
Ken-ichi Okada, Manabu Kawai, Seiko Hirono, Fumiyoshi Kojima, Kensuke Tanioka, Masaki Terada, Motoki Miyazawa, Yuji Kitahata, Yoshifumi Iwahashi, Masaki Ueno, Shinya Hayami, Shin-ichi Murata, Toshio Shimokawa & Hiroki Yamaue. (2020) Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial). Langenbeck's Archives of Surgery 405:1, pages 23-33.
Crossref
ManoopS Bhutani, JasonB Klapman, Richard Tuli, Ghassan El-Haddad, Sarah Hoffe, FranklinC. L. Wong, Beth Chasen, DavidR Fogelman, SimonK Lo, NicholasN Nissen, AndrewE Hendifar, Gauri Varadhachary, MatthewH. G. Katz, WilliamD Erwin, EugeneJ Koay, EricP Tamm, BenS Singh, Rutika Mehta, RobertA Wolff, Ashish Soman, IrinaM Cazacu & JosephM Herman. (2020) An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol. Endoscopic Ultrasound 9:1, pages 24.
Crossref
Christelle Bouchart, Julie Navez, Jean Closset, Alain Hendlisz, Dirk Van Gestel, Luigi Moretti & Jean-Luc Van Laethem. (2020) Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?. Therapeutic Advances in Medical Oncology 12, pages 175883592093609.
Crossref
Elena Incerti, Emilia G. Vanoli, Sara Broggi, Calogero Gumina, Paolo Passoni, Najla Slim, Claudio Fiorino, Michele Reni, Paola Mapelli, Mauro Cattaneo, Silvia Zanon, Riccardo Calandrino, Luigi Gianolli, Nadia Di Muzio & Maria Picchio. (2019) Early variation of 18-fluorine-labelled fluorodeoxyglucose PET-derived parameters after chemoradiotherapy as predictors of survival in locally advanced pancreatic carcinoma patients. Nuclear Medicine Communications 40:10, pages 1072-1080.
Crossref
Vincent P. Groot, Alex B. Blair, Georgios Gemenetzis, Ding Ding, Richard A. Burkhart, Jun Yu, Inne H.M. Borel Rinkes, I. Quintus Molenaar, John L. Cameron, Matthew J. Weiss, Christopher L. Wolfgang & Jin He. (2019) Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. European Journal of Surgical Oncology 45:9, pages 1674-1683.
Crossref
Alba Fiorentino, Riccardo Laudicella, Elisa Ciurlia, Salvatore Annunziata, Valentina Lancellotta, Paola Mapelli, Carmelo Tuscano, Federico Caobelli, Laura Evangelista, Lorenza Marino, Natale Quartuccio, Michele Fiore, Paolo Borghetti, Agostino Chiaravalloti, Maria Ricci, Isacco Desideri & Pierpaolo Alongi. (2019) Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2. Critical Reviews in Oncology/Hematology 139, pages 117-124.
Crossref
Eva-Maria Gassner & Paulina Poskaite. (2019) Imaging response evaluation after novel neoadjuvant treatments of pancreatic cancer. European Surgery 51:3, pages 146-152.
Crossref
Savio G. Barreto, Benjamin Loveday, John A. Windsor & Sanjay Pandanaboyana. (2018) Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer. ANZ Journal of Surgery 89:5, pages 481-487.
Crossref
Lingdi Yin, Yi Miao & Jun Yu. (2019) Advances of pathological complete response after neoadjuvant therapy for pancreatic cancer. Journal of Pancreatology 2:1, pages 11-15.
Crossref
Hiroshi Kurahara, Kosei Maemura, Yuko Mataki, Masahiko Sakoda, Satoshi Iino, Yota Kawasaki, Takaaki Arigami, Shinichiro Mori, Yuko Kijima, Shinichi Ueno, Hiroyuki Shinchi & Shoji Natsugoe. (2018) Significance of 18F-Fluorodeoxyglucose (FDG) Uptake in Response to Chemoradiotherapy for Pancreatic Cancer. Annals of Surgical Oncology 26:2, pages 644-651.
Crossref
Nancy El-Bared, Lorraine Portelance, Benjamin O. Spieler, Deukwoo Kwon, Kyle R. Padgett, Karen M. Brown & Eric A. Mellon. (2019) Dosimetric Benefits and Practical Pitfalls of Daily Online Adaptive MRI-Guided Stereotactic Radiation Therapy for Pancreatic Cancer. Practical Radiation Oncology 9:1, pages e46-e54.
Crossref
Stephen James Ramey, Kyle R. Padgett, Narottam Lamichhane, Hanmath J. Neboori, Deukwoo Kwon, Eric A. Mellon, Karen Brown, Melissa Duffy, James Victoria, Nesrin Dogan & Lorraine Portelance. (2018) Dosimetric analysis of stereotactic body radiation therapy for pancreatic cancer using MR-guided Tri-60Co unit, MR-guided LINAC, and conventional LINAC-based plans. Practical Radiation Oncology 8:5, pages e312-e321.
Crossref
Jin He, Alex B. Blair, Vincent P. Groot, Ammar A. Javed, Richard A. Burkhart, Georgios Gemenetzis, Ralph H. Hruban, Kevin M. Waters, Justin Poling, Lei Zheng, Daniel Laheru, Joseph M. HermanMartin A. Makary, Matthew J. Weiss, John L. Cameron & Christopher L. Wolfgang. (2018) Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?. Annals of Surgery 268:1, pages 1-8.
Crossref
Kei Saito, Hiroyuki Isayama, Yoshihiro Sakamoto, Yousuke Nakai, Kazunaga Ishigaki, Mariko Tanaka, Takeyuki Watadani, Junichi Arita, Naminatsu Takahara, Suguru Mizuno, Hirofumi Kogure, Hideaki Ijichi, Keisuke Tateishi, Minoru Tada, Kiyoshi Hasegawa, Masashi Fukayama, Norihiro Kokudo & Kazuhiko Koike. (2018) A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer. Medical Oncology 35:7.
Crossref
Diego A.S. Toesca, Amanda J. Koong, George A. Poultsides, Brendan C. Visser, Sigurdis Haraldsdottir, Albert C. Koong & Daniel T. Chang. (2018) Management of Borderline Resectable Pancreatic Cancer. International Journal of Radiation Oncology*Biology*Physics 100:5, pages 1155-1174.
Crossref
David J. Birnbaum, Pascal Finetti, Alexia Lopresti, Marine Gilabert, Flora Poizat, Jean-Luc Raoul, Jean-Robert Delpero, Vincent Moutardier, Daniel Birnbaum, Emilie Mamessier & François Bertucci. (2017) A 25-gene classifier predicts overall survival in resectable pancreatic cancer. BMC Medicine 15:1.
Crossref
Laura Maggino & Charles M. VollmerJr.Jr.. (2017) Recent Advances in Pancreatic Cancer Surgery. Current Treatment Options in Gastroenterology 15:4, pages 520-537.
Crossref
Keiichi Okano, Hironobu Suto, Minoru Oshima, Eri Maeda, Naoki Yamamoto, Keitaro Kakinoki, Hideki Kamada, Tsutomu Masaki, Shigeo Takahashi, Toru Shibata & Yasuyuki Suzuki. (2017) A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology 24:9, pages 2777-2784.
Crossref
Stefan Heinrich & Hauke Lang. (2017) Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits. International Journal of Molecular Sciences 18:8, pages 1622.
Crossref
Megan Wachsmann, Raul S. Gonzalez, Zaid Mahdi, Jingsheng Yan & Suntrea Hammer. (2022) Effects of Neoadjuvant Therapy on Pancreatic Ductal Adenocarcinoma Staging, Regression Scoring, and Patient Outcome: A Multi-Institutional Study. SSRN Electronic Journal.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.